Skip to main content
Premium Trial:

Request an Annual Quote

U of Michigan, Tempus Collaborate on Pancreatic Cancer Sequencing

NEW YORK (GenomeWeb) – The University of Michigan and Tempus have announced a collaboration on pancreatic cancer.

Under the terms of the deal, Chicago-based Tempus will provide genomic and gene expression sequencing and analysis to identify treatment opportunities for pancreatic cancer patients at Michigan's comprehensive cancer center.

Pancreatic cancer patients "do not yet have access to a host of targeted therapies with proven effectiveness in the same way that other diseases have, in part because there isn't enough patient, treatment, and outcome data to identify patterns that might lead to actionable treatments," Tempus CEO Eric Lefkofsky said in a statement. Tempus added that the disease has a five-year survival rate of 9 percent.

The deal adds to Tempus' roster of academic medical center clients. The firm has also partnered with University Hospitals Seidman Cancer Center, Rush University Medical Center, the University of Pennsylvania Abramson Cancer Center, and the Mayo Clinic.

Financial and other terms of the arrangement were not disclosed.

The Scan

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.

Australian Survey Points to Public Support for Genetic Risk Disclosure in Relatives of At-Risk Individuals

A survey in the European Journal of Human Genetics suggests most adult Australians are in favor of finding out if a relative tests positive for a medically actionable genetic variant.

Study Links Evolution of Stony Coral Skeleton to Bicarbonate Transporter Gene

A PNAS paper focuses on a skeleton-related bicarbonate transporter gene introduced to stony coral ancestors by tandem duplication.

Hormone-Based Gene Therapy to Sterilize Domestic Cat

A new paper in Nature Communication suggests that gene therapy could be a safer alternative to spaying domestic cats.